Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
109 hedge funds and large institutions have $920M invested in Y-mAbs Therapeutics in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 4 closing their positions.
725% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 4
76% more capital invested
Capital invested by funds: $523M → $920M (+$397M)
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
36% more funds holding
Funds holding: 80 → 109 (+29)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
3.04% more ownership
Funds ownership: 50.49% → 53.53% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$23M |
| 2 |
BlackRock
New York
|
+$12.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.32M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.98M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$4.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$6.32M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.96M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.18M |
| 5 |
AG
Artal Group
Luxembourg
|
-$3.78M |
YMAB Hedge Fund Activity: Q2 2020 in Review
109 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2020, worth a combined $920M — up 76% from $523M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new YMAB positions and 4 closed out — a net gain of 29 holders — while 40 added to existing stakes and 29 trimmed.
The largest buyer was First Light Asset Management, opening a new position worth an estimated $23M. The largest seller was Wellington Management Group, cutting an estimated $15.7M.
- 109 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2020, up from 80 in Q1 2020.
- Funds reported $920M of Y-mAbs Therapeutics stock for Q2 2020, up 76% quarter-over-quarter.
- 33 funds opened new Y-mAbs Therapeutics positions in Q2 2020 and 4 closed out, a net change of +29 holders.
- The largest Y-mAbs Therapeutics buyer in Q2 2020 was First Light Asset Management, an estimated $23M added.
- The largest Y-mAbs Therapeutics seller in Q2 2020 was Wellington Management Group, an estimated $15.7M sold.
Based on aggregated 13F filings for Q2 2020.